Immunicom
Steve is a results-oriented marketing/sales, strategy and business development executive with a 30-year track record of successfully building new growth opportunities and global markets for medical technology companies of all sizes.
He began his career with GE Healthcare where he worked in hospitals across the U.S., Europe and Asia developing the market for nascent technology called positron emission tomography (i.e. PET Imaging), which today is a $2.5 billion global industry. After serving in various VP level roles in Gen-Probe, Cardinal Health, and CareFusion, Steve co-founded CRISI Medical Systems which won the 2015 Frost & Sullivan “North American Award for New Product Innovation”, the 2016 “Medical Design Excellence Award (MDEA)” global competition for drug-delivery devices, and was recently acquired by Becton, Dickinson, and Co.
Steve received his Bachelor of Science in Electrical Engineering degree from Michigan Tech University, his Master of Science in Electrical Engineering from Marquette University, and his MBA from Northwestern University’s Kellogg Graduate School of Management. He has over a dozen issued US & international patents.
Immunicom
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy can allow the body’s natural immune system to directly attack cancer while enhancing the effects of other cancer treatments that may be used concurrently.